Liver Cancer Drugs Market Size Innovations, Trends and Opportunities 2026
According to market projections, the global liver cancer drugs market, valued at USD 3.97 billion in 2026, is anticipated to reach USD 13.13 billion by 2035, growing at a CAGR of 14.2% over the next decade. Liver cancer drugs are medicines used to treat liver cancer by stopping cancer cell growth, shrinking tumors, or boosting the immune system to fight the disease. They include targeted therapies, immunotherapies, chemotherapy, and newer treatments that improve survival and quality of life.
Last Updated : 06 July 2026Category: Therapeutic AreaInsight Code: 5146Format: PDF / PPT / Excel
Regulatory Framework for Leading Countries/Regions
Supply Demand Analysis
Production & Consumption Statistics
Export Import Statistics
Price Trend Analysis
Global Liver Cancer Drugs Market Assessment
Overview
Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Targeted Therapy
Bevacizumab
Cabozantinib
Lenvatinib
Ramucirumab
Regorafenib
Sorafenib
Other Targeted Therapies
Immunotherapy
Atezolizumab with Bevacizumab
Nivolumab with Ipilimumab
Pembrolizumab
Durvalumab with Tremelimumab
Other Immunotherapies
Chemotherapy
Gemcitabine
Oxaliplatin
Cisplatin
Doxorubicin
5-fluorouracil
Capecitabine
Mitoxantrone
Other Chemotherapies
Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
North America
Europe
Asia Pacific
Middle East and Africa
South America
North America Liver Cancer Drugs Market Assessment
Overview
North America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Targeted Therapy
Bevacizumab
Cabozantinib
Lenvatinib
Ramucirumab
Regorafenib
Sorafenib
Other Targeted Therapies
Immunotherapy
Atezolizumab with Bevacizumab
Nivolumab with Ipilimumab
Pembrolizumab
Durvalumab with Tremelimumab
Other Immunotherapies
Chemotherapy
Gemcitabine
Oxaliplatin
Cisplatin
Doxorubicin
5-fluorouracil
Capecitabine
Mitoxantrone
Other Chemotherapies
North America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Europe Liver Cancer Drugs Market Assessment
Overview
Europe Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Targeted Therapy
Bevacizumab
Cabozantinib
Lenvatinib
Ramucirumab
Regorafenib
Sorafenib
Other Targeted Therapies
Immunotherapy
Atezolizumab with Bevacizumab
Nivolumab with Ipilimumab
Pembrolizumab
Durvalumab with Tremelimumab
Other Immunotherapies
Chemotherapy
Gemcitabine
Oxaliplatin
Cisplatin
Doxorubicin
5-fluorouracil
Capecitabine
Mitoxantrone
Other Chemotherapies
Europe Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Asia Pacific Liver Cancer Drugs Market Assessment
Overview
Asia Pacific Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Targeted Therapy
Bevacizumab
Cabozantinib
Lenvatinib
Ramucirumab
Regorafenib
Sorafenib
Other Targeted Therapies
Immunotherapy
Atezolizumab with Bevacizumab
Nivolumab with Ipilimumab
Pembrolizumab
Durvalumab with Tremelimumab
Other Immunotherapies
Chemotherapy
Gemcitabine
Oxaliplatin
Cisplatin
Doxorubicin
5-fluorouracil
Capecitabine
Mitoxantrone
Other Chemotherapies
Asia Pacific Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East and Africa Liver Cancer Drugs Market Assessment
Overview
Middle East and Africa Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Targeted Therapy
Bevacizumab
Cabozantinib
Lenvatinib
Ramucirumab
Regorafenib
Sorafenib
Other Targeted Therapies
Immunotherapy
Atezolizumab with Bevacizumab
Nivolumab with Ipilimumab
Pembrolizumab
Durvalumab with Tremelimumab
Other Immunotherapies
Chemotherapy
Gemcitabine
Oxaliplatin
Cisplatin
Doxorubicin
5-fluorouracil
Capecitabine
Mitoxantrone
Other Chemotherapies
Middle East and Africa Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
South America Liver Cancer Drugs Market Assessment
Overview
South America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Targeted Therapy
Bevacizumab
Cabozantinib
Lenvatinib
Ramucirumab
Regorafenib
Sorafenib
Other Targeted Therapies
Immunotherapy
Atezolizumab with Bevacizumab
Nivolumab with Ipilimumab
Pembrolizumab
Durvalumab with Tremelimumab
Other Immunotherapies
Chemotherapy
Gemcitabine
Oxaliplatin
Cisplatin
Doxorubicin
5-fluorouracil
Capecitabine
Mitoxantrone
Other Chemotherapies
South America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Company Profiles
Bayer AG
Company Overview
Geographic Footprints
Financial Performance
Product Portfolio
SWOT Analysis
R&D Efforts
Recent Developments & Strategic Collaborations
Product Launch/M&A/Technical Collaboration
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
Merck KGaA
Pfizer Inc.
Eisai Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Conclusion & Recommendations
FAQ's
Answer : The global liver cancer drugs market is projected to grow from USD 3.97 billion in 2026 to approximately USD 13.13 billion by 2035, registering a CAGR of 14.2%.
Answer : Despite recent progress, liver cancer treatment still needs a great deal of improvement. These unfulfilled needs include: improved medications for advanced hepatic carcinoma decreased adverse effects and increased efficacy, early identification, and diagnosis.
Answer : Global Cancer Observatory, American Liver Foundation, World Health Organization, National Institute of Health.
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare
market research. As a content reviewer, Aditi ensures the quality and accuracy of all market
insights and data presented by the research team.
We use cookies that are necessary to make our site work. We may also use additional cookies to analyze,
improve, and personalize our content and your digital experience.
You can manage your cookie preferences using the
Privacy Policy
For more information, see our
Terms and Conditions
.
Cookie Preference Center
We use cookies which are necessary to make our site work.
We may also use additional cookies to analyze, improve and personalize
our content and your digital experience.
For more information, please read our
Cookie Policy
.
You may choose not to allow some types of cookies.
Blocking some cookies may impact your experience of the site.